At Exact Sciences, our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. We're hiring! Our organization offers something for everyone, at all stages of careers and from all backgrounds. Let's take on cancer, together.
Lien externe pour Exact Sciences
Our team has been embracing the summer season and showing their support for the Madison community. We’re proud to cheer on local baseball and soccer teams, the Madison Mallards and Forward Madison FC! #WeAreExact
For more than 20 years, the Oncotype DX Breast Recurrence Score® test has been helping clinicians with treatment decisions. This recent publication is yet another example of how continued innovation improves patients' experiences.
Volume 3 Issue 8 of 𝘕𝘌𝘑𝘔 𝘌𝘷𝘪𝘥𝘦𝘯𝘤𝘦 is now available! Here is a preview of the latest content: 𝗢𝗿𝗶𝗴𝗶𝗻𝗮𝗹 𝗔𝗿𝘁𝗶𝗰𝗹𝗲𝘀 Operative versus Nonoperative Treatment of Proximal Hamstring Avulsions https://eviden.cc/4d87cTx Effect of Fenofibrate on Progression of Diabetic Retinopathy https://eviden.cc/3RYG2GX A Patient-Level Meta-Analysis of Intensive Glucose Control in Critically Ill Adults https://eviden.cc/4cdAtvB Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival https://eviden.cc/4de1EXF 𝗥𝗲𝘃𝗶𝗲𝘄 𝗔𝗿𝘁𝗶𝗰𝗹𝗲 Sleep Health https://eviden.cc/4fc7hrm 𝗖𝘂𝗿𝗯𝘀𝗶𝗱𝗲 𝗖𝗼𝗻𝘀𝘂𝗹𝘁 How Do I Approach the Evaluation and Treatment of Lyme Disease? https://eviden.cc/3WbWTap 𝗠𝗼𝗿𝗻𝗶𝗻𝗴 𝗥𝗲𝗽𝗼𝗿𝘁 A 53-Year-Old Woman with Axillary Lymphadenopathy https://eviden.cc/3zSsHcQ Explore all the latest original research and specialty articles in the August issue: https://eviden.cc/current
Today we announced our second-quarter 2024 earnings results. For more information, see our press release here: https://bit.ly/3SvnLBa
Wishing the best of luck to our former #ExactSciencesAthlete, Phoebe Bacon, as she dives in tomorrow at the Olympics! The Exact Sciences team is cheering you on, Phoebe! 🏊♀️ #Paris2024
We love our interns! It’s #NationalInternDay and we are lucky to be celebrating 106 talented individuals from all over the country. Our interns complete projects across several business functions and still find time to volunteer in their communities. It’s safe to say they have already made an impact this summer. #WeAreExact
Despite progress against colorectal cancer, continuing racial disparities mean Black adults are still more likely to develop and die from this disease. A new paper, published in Journal of the National Cancer and based on research sponsored by Exact Sciences, offers new opportunities to address these disparities. The model predicts that eliminating racial disparities in follow-up colonoscopy and colonoscopy quality would dramatically reduce colorectal cancer incidence and deaths among Black adults. Read more here: https://lnkd.in/gsQNeYCw Thank you to all the co-authors for your collaboration on this important work. Together, we’ll continue to work to address health equity in cancer care.
Being re-certified as a Great Place To Work US for the 6th consecutive year means our efforts towards fostering a positive, collaborative, and innovative workplace are making a difference. We are thankful for our incredible team; with their input, we can continuously grow and improve to ensure Exact Sciences is a great place to work for all. #WeAreExact
Join us in congratulating our very own Jorge Garces on being recognized as a San Diego Business Journal Leader of Influence in Life Sciences! Congratulations, Jorge, and thanks for all you do to advance our purpose to help eradicate cancer. https://bit.ly/3WBmF8n
Great article about the importance of personalized cancer care below. Follow our Exact Sciences Precision Oncology page for more updates!
When selecting therapies for patients with #advancedcancer, a personalized approach is crucial. Rick Baehner, MD, discusses the importance of next-generation sequencing (NGS) technologies, like the OncoExTra® test, during therapy selection in the new Medical Device Network article, "NGS: the road to personalising cancer care." Read the full article: https://bit.ly/3XJGhch
Breast cancer care has come a long way, including a shift towards personalized treatment with tools like the Oncotype DX® test, which provides insights based on an individual’s specific tumor biology. Read more about the importance of expanding global access to these genomic tests via Open Access Government: https://bit.ly/3zP85lQ
EXAS
NASDAQ
20 minutes de retard
54,42 $US
-2,935 (-5,118%)
Données de Refinitiv
Voir plus d’infos surDernier round
Dette après introduction en Bourse620 700 000,00 $US